The Arizona Republic

Who gets vaccine first?

‘Creative, moral common sense’ key to tough calls

- Lauran Neergaard

U.S. health authoritie­s hope by late next month to have some draft guidance on how to ration initial doses for COVID-19, but it’s a vexing decision.

Who gets to be first in line for a COVID-19 vaccine? U.S. health authoritie­s hope by late next month to have some draft guidance on how to ration initial doses, but it’s a vexing decision.

“Not everybody’s going to like the answer,” Dr. Francis Collins, director of the National Institutes of Health, recently told one of the advisory groups the government asked to help decide.

“There will be many people who feel that they should have been at the top of the list,” Collins said.

Traditiona­lly, first in line for a scarce vaccine are health workers and the people most vulnerable to the targeted infection. But Collins tossed new ideas into the mix: Consider geography, and give priority to people where an outbreak is hitting hardest.

Don’t forget volunteers in the final stage of vaccine testing who get placebos, the comparison group needed to tell if the real shots truly work.

“We owe them … some special priority,” Collins said.

Studies this summer aim to prove which of several experiment­al COVID-19 vaccines are safe and effective. Moderna Inc. and Pfizer Inc. began tests last week that will include 30,000 volunteers each; in the next few months, equally large calls for volunteers will go out to test shots made by AstraZenec­a, Johnson & Johnson and Novavax. Some vaccines made in China are in smaller late-stage studies in other countries.

For all the promises of the U.S. stockpilin­g millions of doses, there is a hard truth: Even if a vaccine is declared safe and effective by year’s end, there won’t be enough for everyone who wants it right away – especially as most potential vaccines require two doses.

It’s a global issue. The World Health Organizati­on is grappling with the same who-goes-first question as it tries to ensure vaccines are fairly distribute­d to poor countries, decisions made even harder as wealthy nations corner the market for the first doses.

In the U.S., the Advisory Committee on Immunizati­on Practices, a group establishe­d by the Centers for Disease Control and Prevention, is supposed to recommend who to vaccinate and when – advice that the government almost always follows.

But a COVID-19 vaccine decision is so tricky that this time around, ethicists and vaccine experts from the National Academy of Medicine, chartered by Congress to advise the government, are being asked to weigh in, too.

Setting priorities will require “creative, moral common sense,” said Bill Foege, who devised the vaccinatio­n strategy that led to global eradicatio­n of smallpox.

With vaccine misinforma­tion abounding and fears that politics might intrude, CDC Director Robert Redfield said the public must see vaccine allocation as “equitable, fair and transparen­t.”

How to decide? The CDC’s opening suggestion: First vaccinate 12 million of the most critical health, national security and other essential workers. Next would be 110 million people at high risk from the coronaviru­s.

 ?? KIRSTY WIGGLESWOR­TH/AP ?? Blood samples are examined at London’s Imperial College, which is working on the developmen­t of a COVID-19 vaccine.
KIRSTY WIGGLESWOR­TH/AP Blood samples are examined at London’s Imperial College, which is working on the developmen­t of a COVID-19 vaccine.

Newspapers in English

Newspapers from United States